Adam J. Gadzinski, MD, MS, on Study Results Assessing the Impact of Telemedicine on Patient-Reported Outcomes

Video

The study was designed to determine the impact of a rurally focused telemedicine program on patient outcomes.

In a study presented at the Society of Urologic Oncology 21st Annual Meeting, researchers sought to determine the impact of a rurally focused telemedicine program on patient outcomes in the urologic oncology outpatient clinic at the University of Washington Medical Center (UWMC).

In an interview with CancerNetwork®, Adam J. Gadzinski, MD, MS, urologic oncology fellow and an acting instructor of Urologic Oncology at the Urology Clinic at UWMC, discussed the findings from this study.

Transcription:

So, what we found is that overall patient satisfaction was generally the same between both in person and telemedicine visits. But, no surprises, telemedicine didn't require essentially any travel, and at the University of Washington we tend to be a referral center for the state of Alaska and some of the other Pacific Northwest states, so some of our patients were spending a tremendous amount of money just to come and see us for outpatient visit appointments. And of our in-person visits, we found that almost 10% were spending over $1000 to come and see us in person, not to have surgery, just for an office visit; and telemedicine eliminated essentially all of those travel costs.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content